Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study-Reference-Cited by-同舟云学术

Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study

Published:2021-11 Issue:11 Volume:8 Page:e668-e678
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Orkin Chloe,Bernal Morell Enrique,Tan Darrell H S,Katner Harold,Stellbrink Hans-Jürgen,Belonosova Elena,DeMoor Rebecca,Griffith Sandy,Thiagarajah Shanker,Van Solingen-Ristea Rodica,Ford Susan L,Crauwels Herta,Patel Parul,Cutrell Amy,Smith Kimberly Y,Vandermeulen Kati,Birmingham Eileen,St Clair Marty,Spreen William R,D'Amico Ronald

Funder

Janssen Research and Development LLC

ViiV Healthcare UK

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference27 articles.

1. Adherence to antiretroviral therapy and virologic failure: a meta-analysis;Bezabhe;Medicine,2016

2. Adherence to antiretroviral therapy and its effect on survival of HIV-infected individuals in Jharkhand, India;Rai;PLoS One,2013

3. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy;Bangsberg;J Antimicrob Chemother,2004

4. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies;Llibre;Lancet,2018

5. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine;Journal of Antimicrobial Chemotherapy;2024-07-27

2. Early Implementation and Outcomes Among People with HIV Who Accessed Long-Acting Injectable Cabotegravir/Rilpivirine at Two Ryan White Clinics in the U.S. South;AIDS Research and Human Retroviruses;2024-07-16

3. Antirétroviral injectable à action prolongée pour l’infection à VIH-1 chez l’adulte;Canadian Medical Association Journal;2024-07-14

4. Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07

5. One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study;Open Forum Infectious Diseases;2024-06-20